Future ATMP Manufacturing Paradigms, Part 2

By Dave Seaward, founder and engineering director, 3P Innovation

The ATMP manufacturing landscape is evolving beyond traditional pharmaceutical models. While core processes may remain, expect refinement for throughput and quality, potentially shifting larger-volume processes from batch to continuous manufacturing. A key divergence is emerging between therapies suited for functionally closed systems (using complex, potentially unrecognizable consumable bag sets) and those requiring closed isolators, likely incorporating robotics for gloveless, reliable processing.

Sensing and feedback control will become increasingly sophisticated in both paradigms. Furthermore, the production footprint will vary; while some therapies follow centralized factory models, the patient-specific nature of others necessitates decentralized "hub and spoke" manufacturing networks with different automation needs. Scalability from benchtop to commercial production will be paramount for all equipment vendors. What will the ATMP factory of the future look like?

Download the full article for insights into future ATMP manufacturing paradigms.